Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Times Interest Earned (2019 - 2025)

Karyopharm Therapeutics' Times Interest Earned history spans 9 years, with the latest figure at $2.51 for Q4 2025.

  • For Q4 2025, Times Interest Earned rose 189.99% year-over-year to $2.51; the TTM value through Dec 2025 reached -$0.9, up 71.87%, while the annual FY2025 figure was -$0.9, 71.87% up from the prior year.
  • Times Interest Earned reached $2.51 in Q4 2025 per KPTI's latest filing, up from -$1.38 in the prior quarter.
  • In the past five years, Times Interest Earned ranged from a high of $5.91 in Q4 2021 to a low of -$10.28 in Q1 2021.
  • Average Times Interest Earned over 5 years is -$4.11, with a median of -$5.13 recorded in 2023.
  • Peak YoY movement for Times Interest Earned: skyrocketed 212.85% in 2021, then crashed 197.3% in 2022.
  • A 5-year view of Times Interest Earned shows it stood at $5.91 in 2021, then crashed by 197.3% to -$5.76 in 2022, then decreased by 5.82% to -$6.09 in 2023, then surged by 54.16% to -$2.79 in 2024, then skyrocketed by 189.99% to $2.51 in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Times Interest Earned are $2.51 (Q4 2025), -$1.38 (Q3 2025), and -$2.17 (Q2 2025).